129 related articles for article (PubMed ID: 37596839)
1. Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.
Marathe DD; Jauslin PM; Kleijn HJ; de Miranda Silva C; Chain A; Bateman T; Shaw PM; Abraham AK; Kauh EA; Liu Y; Perini RF; de Alwis DP; Jain L
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1499-1510. PubMed ID: 37596839
[TBL] [Abstract][Full Text] [Related]
2. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
[TBL] [Abstract][Full Text] [Related]
3. Belzutifan: A Narrative Drug Review.
Visweswaran V; Pavithran K
Curr Drug Res Rev; 2022; 14(2):88-95. PubMed ID: 35366789
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
Fallah J; Brave MH; Weinstock C; Mehta GU; Bradford D; Gittleman H; Bloomquist EW; Charlab R; Hamed SS; Miller CP; Dorff SE; Chambers WA; Mixter BD; Dinin J; Pierce WF; Ricks TK; Tang S; Donoghue M; Pazdur R; Amiri-Kordestani L; Ibrahim A; Beaver JA
Clin Cancer Res; 2022 Nov; 28(22):4843-4848. PubMed ID: 35727604
[TBL] [Abstract][Full Text] [Related]
5. Belzutifan: First Approval.
Deeks ED
Drugs; 2021 Nov; 81(16):1921-1927. PubMed ID: 34613603
[TBL] [Abstract][Full Text] [Related]
6. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.
Curry L; Soleimani M
Future Oncol; 2024 Apr; ():. PubMed ID: 38639572
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Choueiri TK; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Michaelson MD; Appleman LJ; Thamake S; Perini RF; Zojwalla NJ; Jonasch E
Nat Med; 2021 May; 27(5):802-805. PubMed ID: 33888901
[TBL] [Abstract][Full Text] [Related]
8. Neurological applications of belzutifan in von Hippel-Lindau disease.
Zhang Y; Nguyen CC; Zhang NT; Fink NS; John JD; Venkatesh OG; Roe JD; Hoffman SC; Lesniak MS; Wolinsky JP; Horbinski C; Szymaniak BM; Buerki RA; Sosman JA; Shenoy NK; Lukas RV
Neuro Oncol; 2023 May; 25(5):827-838. PubMed ID: 36215167
[TBL] [Abstract][Full Text] [Related]
9. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
Hasanov E; Jonasch E
Expert Opin Investig Drugs; 2021 May; 30(5):495-504. PubMed ID: 33945366
[TBL] [Abstract][Full Text] [Related]
10. Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor.
Pelle E; Al-Toubah T; Morse B; Strosberg J
J Natl Compr Canc Netw; 2022 Dec; 20(12):1285-1287. PubMed ID: 36509068
[TBL] [Abstract][Full Text] [Related]
11. Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.
Choi WW; Boland JL; Kalola A; Lin J
Curr Oncol Rep; 2023 Feb; 25(2):123-129. PubMed ID: 36630072
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of axitinib.
Chen Y; Tortorici MA; Garrett M; Hee B; Klamerus KJ; Pithavala YK
Clin Pharmacokinet; 2013 Sep; 52(9):713-25. PubMed ID: 23677771
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Jain L; Woo S; Gardner ER; Dahut WL; Kohn EC; Kummar S; Mould DR; Giaccone G; Yarchoan R; Venitz J; Figg WD
Br J Clin Pharmacol; 2011 Aug; 72(2):294-305. PubMed ID: 21392074
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes.
Nagase M; Shimada H; Nii M; Ueda S; Higashimori M; Ichikawa K; Zhang L; Zhou L; Chen Y; Zhou D; Dunyak J; Al-Huniti N
J Clin Pharm Ther; 2020 Oct; 45(5):1030-1038. PubMed ID: 32227647
[TBL] [Abstract][Full Text] [Related]
15. Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience.
Neth BJ; Webb MJ; White J; Uhm JH; Pichurin PN; Sener U
J Neurooncol; 2023 Aug; 164(1):239-247. PubMed ID: 37450072
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors.
Goel V; Hurh E; Stein A; Nedelman J; Zhou J; Chiparus O; Huang PH; Gogov S; Sellami D
Cancer Chemother Pharmacol; 2016 Apr; 77(4):745-55. PubMed ID: 26898300
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults.
Lin S; Nikanjam M; Capparelli EV; Allegrini A; Pavone D; Yim DS; Hammami MM; Bertino JS; Nafziger AN; Park YS; Kang JS; Yin OQ; Ma JD
Ther Drug Monit; 2018 Dec; 40(6):754-758. PubMed ID: 30045358
[TBL] [Abstract][Full Text] [Related]
18. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.
Iacovelli R; Arduini D; Ciccarese C; Pierconti F; Strusi A; Piro G; Carbone C; Foschi N; Daniele G; Tortora G
Crit Rev Oncol Hematol; 2022 Aug; 176():103750. PubMed ID: 35728738
[TBL] [Abstract][Full Text] [Related]
19. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance.
Louise M Binderup M; Smerdel M; Borgwadt L; Beck Nielsen SS; Madsen MG; Møller HU; Kiilgaard JF; Friis-Hansen L; Harbud V; Cortnum S; Owen H; Gimsing S; Friis Juhl HA; Munthe S; Geilswijk M; Rasmussen ÅK; Møldrup U; Graumann O; Donskov F; Grønbæk H; Stausbøl-Grøn B; Schaffalitzky de Muckadell O; Knigge U; Dam G; Wadt KA; Bøgeskov L; Bagi P; Lund L; Stochholm K; Ousager LB; Sunde L
Eur J Med Genet; 2022 Aug; 65(8):104538. PubMed ID: 35709961
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]